AI news impact · China A-shares
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A (301096) news impact
On 2026-11-12 Wave Radar's AI rated the news on Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A as neutral (impact score +25%).
Baicheng Medical reported Q1-Q3 2026 total revenue of 450 million yuan and appeared on ChiNext margin balance increase rankings.
- Direction
- Neutral
- Impact score
- +25%
- Confidence
- 75%
- Headlines read
- 2
- Date
- 2026-11-12
AI assessment
Steady revenue of 450 million yuan reflects operational stability, accompanied by mild margin buying interest to support sentiment.
Sector impact
Neutral to minimal impact on the broader CRO and pharmaceutical R&D sector.
Headlines the AI read
- 创业板股融资余额增幅榜(附股) AkShare/证券时报网 · 2026-11-10
- 百诚医药:2026年前三季度实现营业总收入4.5亿元 AkShare/中国证券报·中证网 · 2026-10-28
Rating history
One rating per trading day the stock was covered.
More on Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A
How the rating works
After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.